Abstract
A biological characterization of tumor tissue is mandatory in NSCLC patients to identify cases at high risk of recurrence and to drive current targeted therapies such as EGFR and ALK inhibitors. In addition, promising results have been reported on the utility of molecular parameters for the prediction of the efficacy of systemic cytotoxic therapy. MicroRNAs (miRNAs) are small single stranded non-coding RNA molecules, which regulate gene expression at the posttranscriptional level. Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes, determine prognosis and response to therapy. This review aims to summarize the current literature on this rapidly evolving field.
Keywords: miRNA, prognostic, predictive, therapy, NSCLC.
Current Pharmaceutical Design
Title:MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Volume: 20 Issue: 24
Author(s): D. Cortinovis, V. Monica, F Pietrantonio, G.L. Ceresoli, C.M. La Spina and L. Wannesson
Affiliation:
Keywords: miRNA, prognostic, predictive, therapy, NSCLC.
Abstract: A biological characterization of tumor tissue is mandatory in NSCLC patients to identify cases at high risk of recurrence and to drive current targeted therapies such as EGFR and ALK inhibitors. In addition, promising results have been reported on the utility of molecular parameters for the prediction of the efficacy of systemic cytotoxic therapy. MicroRNAs (miRNAs) are small single stranded non-coding RNA molecules, which regulate gene expression at the posttranscriptional level. Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes, determine prognosis and response to therapy. This review aims to summarize the current literature on this rapidly evolving field.
Export Options
About this article
Cite this article as:
Cortinovis D., Monica V., Pietrantonio F, Ceresoli G.L., Spina La C.M. and Wannesson L., MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises, Current Pharmaceutical Design 2014; 20 (24) . https://dx.doi.org/10.2174/13816128113196660755
DOI https://dx.doi.org/10.2174/13816128113196660755 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
Current Medicinal Chemistry Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology Discovery of Cationic Polymers for Non-Viral Gene Delivery Using Combinatorial Approaches
Combinatorial Chemistry & High Throughput Screening Liver-Based In Vitro Technologies for Drug Biotransformation Studies - A Review
Current Drug Metabolism Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Inhalable Nanostructures for Lung Cancer Treatment: Progress and Challenges
Current Nanomedicine Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Triple Negative Breast Cancer: A Tale of Two Decades
Anti-Cancer Agents in Medicinal Chemistry Nanoembedded Microparticles for Stabilization and Delivery of Drug-Loaded Nanoparticles
Current Pharmaceutical Design Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Current Stem Cell Research & Therapy Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Current Drug Metabolism Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery